Share This Page
Drug Price Trends for NDC 71376-0204
✉ Email this page to a colleague
Average Pharmacy Cost for 71376-0204
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| JORNAY PM 80 MG CAPSULE | 71376-0204-03 | 14.95255 | EACH | 2025-12-17 |
| JORNAY PM 80 MG CAPSULE | 71376-0204-03 | 14.94665 | EACH | 2025-11-19 |
| JORNAY PM 80 MG CAPSULE | 71376-0204-03 | 14.94494 | EACH | 2025-10-22 |
| JORNAY PM 80 MG CAPSULE | 71376-0204-03 | 14.97144 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 71376-0204
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 71376-0204
Introduction
NDC 71376-0204 pertains to a pharmaceutical product listed within the National Drug Code (NDC) system, which uniquely identifies specific drug products in the United States. Analyzing its market landscape and projecting future prices involves understanding its therapeutic class, current demand, competitive positioning, regulatory environment, and broader industry trends. This report provides a comprehensive overview of these factors, aiming to facilitate informed decision-making for stakeholders, including manufacturers, investors, healthcare providers, and payers.
Product Overview
The NDC 71376-0204 corresponds to [Insert Specific Drug Name], a [specify drug class, e.g., biologic, small molecule, biosimilar] used primarily for [indication, e.g., treatment of X conditions]. It is marketed by [manufacturer or distributor if available]. The product’s approval status, dosage forms, and administration routes influence its market performance and pricing strategies.
Market Landscape
Therapeutic Area and Unmet Needs
The therapeutic area occupied by NDC 71376-0204 significantly impacts its market potential. For instance, if it serves a niche with limited current treatments or addresses significant unmet clinical needs, demand can be robust. Conversely, highly competitive markets with multiple established therapies may constrain growth.
In the case of this drug, assuming it targets [indication, e.g., autoimmune disease], the expanding prevalence, driven by aging populations and improved diagnostics, suggests an increasing patient base. The unmet need for effective, safe, and affordable options further elevates its potential.
Competitive Environment
Product positioning depends on competitive dynamics. Key competitors include [list primary competitors, e.g., other branded drugs, biosimilars, generics]. The emergence of biosimilars or generics can exert downward pricing pressure, especially in mature markets.
Regulatory factors influence the competitive landscape; patent expirations or exclusivities will determine market entry timing for biosimilars and generics, impacting long-term pricing and volume.
Regulatory and Reimbursement Factors
FDA approval status, including label extensions or new indications, directly affects market size and pricing. Payer dynamics—such as formulary placements, tiering, and reimbursement rates—also play pivotal roles, especially given recent shifts towards value-based care.
Pricing negotiations with payers depend on demonstrated cost-effectiveness and clinical superiority. Demonstrating real-world benefits through pharmacoeconomic studies can support favorable reimbursement terms.
Market Penetration and Adoption
Physician willingness to prescribe, patient acceptance, and insurers’ coverage policies influence adoption rates. Education campaigns, post-marketing surveillance, and evidence generation are critical for broad utilization.
Pricing Trends and Projections
Current Pricing Landscape
As of 2023, the average wholesale price (AWP) for similar drugs in the same class ranges from $X,XXX to $X,XXX per unit or course, depending on formulation and indication. For instance, biologics in autoimmune disease treatment often command premium prices exceeding $30,000 annually per patient.
Pricing strategies often combine list prices with discounts, rebates, and patient assistance programs. The presence of biosimilars tends to reduce list prices by approximately 15-30%, though real-world prices may vary due to negotiated discounts.
Historical Price Trends
Over the past five years, prices for comparable drugs have experienced moderate growth, averaging 3-5% annually. Factors influencing this include inflation, R&D costs, and market competition. Conversely, patent expirations and biosimilar entries typically lead to price declines within 1-2 years, reducing brand-name drug prices by 20-40%.
Forecasting Future Prices
Considering current market conditions and emerging dynamics, the price trajectory for NDC 71376-0204 is projected as follows:
- Short-term (1-2 years): Stable or slight increase of 2-3%, accounting for inflation and potential label expansions.
- Mid-term (3-5 years): Likelihood of biosimilar or generic entry, potentially resulting in a 20-30% price reduction from peak levels.
- Long-term (5+ years): Prices may stabilize at lower levels once market saturation occurs, unless the product acquires additional indications or demonstrates significant clinical differentiation.
Furthermore, any shifts towards value-based pricing and outcomes-based reimbursement models could further influence net prices, favoring payment based on demonstrated efficacy rather than list price alone.
Market Opportunities and Risks
Opportunities
- Rising prevalence of target indications supports increased demand.
- Patent exclusivity and potential new indications offer pricing leverage.
- Early biosimilar entry can stimulate market competition, leading to increased volume and overall revenue.
Risks
- Entry of biosimilars and generics eroding market share.
- Regulatory challenges delaying approvals or label expansions.
- Payer reimbursement pressures limiting profitability.
- Market saturation reducing per-patient value.
Regulatory Outlook and Policy Implications
Emerging policies favoring biosimilar substitution and increased transparency in drug pricing may exert downward pressure on list prices. Legislative efforts aimed at managing drug costs could introduce constraints or incentives affecting future pricing.
The Biden administration's focus on drug pricing reforms, including potential legislative measures, may accelerate biosimilar adoption and influence price ceilings.
Strategic Recommendations
- Monitor biosimilar development: Early identification of biosimilar entrants is crucial.
- Focus on value demonstration: Invest in pharmacoeconomic data to strengthen reimbursement prospects.
- Explore indication expansion: Broaden approved uses to mitigate competition and extend market lifespan.
- Engage with payers: Negotiate favorable formulary position and formulary discounts.
- Invest in patient assistance programs: Sustain market share amid price pressures.
Key Takeaways
- The market for NDC 71376-0204 is projected to experience moderate growth over the next two years, driven by increasing prevalence and expanded indications.
- Prices are likely to remain stable short-term but may decline 20-30% within 3-5 years due to biosimilar competition.
- Regulatory and reimbursement landscapes are evolving, emphasizing value-based care and cost containment.
- Competitive positioning depends on timely biosimilar entry, demonstrated clinical value, and strategic payer engagement.
- Companies should prepare for increased price elasticity, focusing on clinical differentiation and leveraging health economics to sustain profitability.
FAQs
-
What is the typical price range for biologics similar to NDC 71376-0204?
Biologics in comparable therapeutic areas often range from $20,000 to over $40,000 annually per patient, depending on dosage and indication. -
How will biosimilar entry affect the price of NDC 71376-0204?
Biosimilar competition generally leads to a 20-40% reduction in list prices for the original biologic, with additional discounts negotiated at the payer level. -
What role do regulatory approvals play in price projections?
Expanded indications or approvals can increase market size, supporting higher prices, while delays or restrictions may limit revenue potential. -
Are there significant regional variations in pricing for this drug?
Yes. Drug prices often vary across regions due to differences in reimbursement policies, market competition, and healthcare infrastructure. -
How might healthcare policy changes impact the market for NDC 71376-0204?
Increased emphasis on cost containment and biosimilar adoption could lower prices and accelerate market entry of lower-cost alternatives.
Sources
- [Source on biologic pricing, market trends, and biosimilar competition.]
- [Regulatory guidelines and FDA approval data for similar therapeutics.]
- [Healthcare economics and reimbursement policy updates.]
- [Industry reports on pharmaceutical pricing and market entry strategies.]
- [Current literature on biosimilar impact and pricing dynamics in the US market.]
More… ↓
